Jasper Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023; filed November 9, 2023. Jasper is a clinical-stage biotechnology company developing briquilimab for mast-cell-driven diseases and stem-cell transplant and hematologic settings. It has no approved products and has generated no product-sale revenue.
Financial results and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $14.8 million | $9.0 million | $38.0 million | $25.3 million |
| General and administrative expense | $4.5 million | $3.7 million | $13.2 million | $12.1 million |
| Total operating expenses | $19.4 million | $12.7 million | $51.1 million | $37.4 million |
| Net loss | $17.5 million | $11.9 million | $47.9 million | $24.5 million |
| Net loss per share, basic and diluted | $0.16 | $0.32 | $0.47 | $0.67 |
For the nine months, operating cash outflow was $35.6 million versus $33.2 million a year earlier; investing outflow was $0.04 million versus $0.5 million; and financing inflow was $101.2 million versus less than $0.1 million. Cash, cash equivalents and restricted cash increased by $65.6 million to $104.3 million. At September 30, cash and cash equivalents were $103.9 million, total liabilities were $16.3 million, and stockholders’ equity was $94.1 million. The company reported no outstanding debt.
Margins are not meaningful because Jasper had no product revenue. Its accumulated deficit was $153.0 million at September 30. Management expects existing cash to fund its current operating plan for at least 12 months from the filing date, but says additional financing will be needed for continued development.
Material changes and notable items
- Operating expenses rose 52% in Q3 and 37% for the nine-month period year over year, driven mainly by higher R&D spending. Nine-month R&D increased 50%, principally from manufacturing and clinical-development costs; chronic urticaria program spending began in 2023.
- Net loss increased 96% for the nine-month period. The comparison is affected by $12.7 million of combined warrant- and earnout-liability fair-value gains in 2022; the warrant liability was reclassified to equity in January 2023 and is no longer remeasured. Nine-month 2023 interest income rose to $4.0 million from $0.4 million, largely because of higher cash balances and interest rates.
- In January 2023, Jasper raised $96.9 million net in an underwritten offering of 69.0 million shares and $4.5 million net through its ATM offering. Common shares outstanding rose from 38.0 million at year-end 2022 to 110.9 million at September 30, 2023. The shelf registration allows up to $250 million of offerings, including an ATM facility of up to $75 million; as of November 8, $175 million remained unallocated under the shelf and $75 million available under the ATM.
- The Stanford license for briquilimab was amended in July 2023 to modify certain milestones. A final $0.3 million milestone under the Stanford-sponsored Fanconi anemia research agreement was achieved and expensed in July.
Outlook, risks and contingencies
- Management expects R&D and general and administrative expenses to increase as clinical trials, manufacturing, staffing and public-company activities continue. No specific revenue, earnings or expense guidance was provided.
- Briquilimab is being developed in chronic spontaneous and inducible urticaria, lower/intermediate-risk MDS and transplant-conditioning settings, including SCID. The filing describes ongoing or planned clinical work, but provides no quantified clinical outcomes in the supplied text.
- Jasper depends on contract manufacturers, including Lonza, and has limitations on switching suppliers under its manufacturing arrangements. Manufacturing costs, clinical execution, regulatory outcomes and access to capital remain significant risks.
- The company states that it must raise further capital and that financing may not be available on acceptable terms; failure to obtain it could force delays, reductions or discontinuation of programs. Equity fundraising may dilute existing holders. Its disclosures note substantial doubt about viability beyond the 12-month period, while management expects current cash to cover at least 12 months from filing.
- On October 18, 2023, Nasdaq notified Jasper that its bid price had been below $1.00 for 30 consecutive business days. The initial compliance deadline is April 15, 2024; the company may consider a reverse stock split, but regaining compliance is not assured.
- Jasper disclosed no material legal proceedings. It reported effective disclosure controls and no material changes in internal control over financial reporting during the quarter. The filing also discusses financial-market, geopolitical, foreign-exchange, intellectual-property, clinical-development and dilution risks.
Investor verification priorities
- Confirm current cash burn, cash runway assumptions and financing plans, including subsequent shelf or ATM activity and the resulting dilution.
- Track clinical-trial enrollment, timelines, safety and efficacy data for briquilimab across urticaria, MDS and transplant programs.
- Monitor Nasdaq bid-price compliance and any proposed reverse stock split or other listing actions.
- Assess manufacturing capacity, costs and supplier dependence, as well as the status and obligations of the Amgen, Stanford and CIRM arrangements.
- Reconcile the reported cash and cash-equivalent balance with the filing’s disclosure of funds held at Silicon Valley Bridge Bank; Jasper said it had full access to and control over its funds at the filing date.